

Drug Monograph

Drug Name: **Nymalize® (nimodipine) oral solution**
 Drug Class: **Cardiovascular: Calcium Channel Blockers, Dihydropyridines**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Nymalize is now available in a 60 mg/10 ml oral solution which comes in an 8 ounce bottle or 5 ml and 10 ml prefilled syringes.

Manufacturer: Distributed by: Arbor Pharmaceuticals, LLC, Atlanta, GA 30328.

Indications: Nymalize is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e. Hunt and Hess Grades I-V).

Costs: \$1995.54 per 237 ml bottle of 60 mg/10 ml oral solution. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD
 Date: September 1, 2021